Next 10 |
2024-04-25 10:00:28 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance BofA watched clients retract $2B last week as the S&P dropped ...
2024-04-25 07:56:55 ET More on Bristol-Myers Squibb Company Is Bristol Myers Squibb A Buy At These Bottom Levels? Bristol-Myers Squibb: Market Pessimism Won't Last Forever Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade) Bristol-...
2024-04-19 06:13:03 ET More on Bristol-Myers Squibb, Gilead, etc. Johnson & Johnson: Buy This Bargain Before It's Gone Bristol-Myers Squibb: Market Pessimism Won't Last Forever Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript FDA approves Alvo...
2024-04-08 00:00:02 ET Citigroup analyst issues BUY recommendation for TSVT on April 7, 2024 04:22PM ET. The previous analyst recommendation was Buy. TSVT was trading at $4.92 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-04-06 08:38:09 ET More on Johnson & Johnson Johnson & Johnson: Self-Proclaimed 'Dividend King' Faces Tricky Outlook With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back Johnson & Johnson (JNJ) Barclays 26th Annual Global Healthcare ...
2024-04-05 09:33:47 ET Bristol Myers Squibb ( NYSE: BMY ) said on Friday that the company and 2seventy bio ( NASDAQ: TSVT ) received U.S. FDA approval for Abecma in the treatment of adult patients with relapsed or refractory multiple myeloma.... Rea...
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile Expanded approval brings this personalized CAR T cell therapy to more pati...
2024-04-03 17:24:42 ET Gainers: Signature Bank ( OTC:SBNY ) +10% . MacroGenics ( MGNX ) +9% . Simulations Plus ( SLP ) +7% . Annexon ( ANNX ) +6% . 2seventy ( TSVT ) +5% . Losers: Cadiz ( CDZIP ) -11% . ...
2024-04-03 09:34:51 ET Summary 2seventy bio is focusing on ABECMA, their CAR-T cell therapy for multiple myeloma, and expects label expansion approval. ABECMA has shown positive real-world evidence and has the potential for significant market growth. The company's financial po...
- Company Now Exclusively Focused on Development and Commercialization of Abecma - 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has ac...
News, Short Squeeze, Breakout and More Instantly...
2seventy bio Inc. Company Name:
TSVT Stock Symbol:
NASDAQ Market:
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings??...
2024-04-08 00:00:02 ET Citigroup analyst issues BUY recommendation for TSVT on April 7, 2024 04:22PM ET. The previous analyst recommendation was Buy. TSVT was trading at $4.92 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
Friday, the FDA approved Bristol-Myers Squibb Company (NYSE:BMY) and 2seventy Bio Inc’s (NASDAQ:TSVT) Abecma&n...